Biodesix

Biodesix offers Nodify XL2 and Nodify CDT for lung nodule risk assessment. Nodify XL2 integrates clinical factors with two plasma proteins to rule out malignancy with high negative predictive value, while Nodify CDT evaluates a broader panel of circulating protein markers to assess risk. Both are performed in the company's own CLIA-certified laboratory in Louisville, Colorado.

Revenue splits across two segments: clinical diagnostic services sold to physicians and hospitals, and biopharmaceutical development services where Biodesix runs companion diagnostic testing and validation for drug developers. The clinical business bills payers and institutions for each test performed; the biopharma business generates service fees and milestone-based payments tied to clinical trials.

Yes. Biodesix completed a business combination with a special purpose acquisition company in 2021 and now trades on the Nasdaq under the ticker BDSX. This provides public financial disclosures and SEC filings that investors can review for commercial performance.

Biodesix runs a CLIA-certified, CAP-accredited central laboratory at its Louisville, Colorado headquarters, plus an additional laboratory site in De Soto, Kansas. The labs perform proteomic testing via MALDI-ToF mass spectrometry and genomic analysis via next-generation sequencing, processing physician-ordered and clinical-trial samples in house.

The company's menu focuses specifically on lung disease — including pulmonary nodule evaluation and treatment selection for non-small cell lung cancer. Tests like VeriStrat provide proteomic profiling to guide therapy choices, while GeneStrat offers genomic tumor profiling from a blood draw. The platform does not currently extend to other solid-tumor or hematologic cancers.